Marco Cavalli1, Gang Pan1, Helena Nord1, Emelie Wallén Arzt1,2, Ola Wallerman1, Claes Wadelius1. 1. Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. 2. Department of Biosciences and Nutrition, Center for Biosciences, Karolinska Institute, Huddinge, Sweden.
Abstract
AIM: Infection by hepatitis C virus (HCV) can result in the development of liver fibrosis and may eventually progress into cirrhosis and hepatocellular carcinoma. However, the molecular mechanisms for this process are not fully known. Several genome-wide association studies have been carried out to pinpoint causative variants in HCV-infected patient cohorts, but these variants are usually not the functional ones. The aim of this study was to identify the regulatory single nucleotide polymorphism associated with the risk of HCV-induced liver fibrosis and elucidate its molecular mechanism. METHODS: We utilized a bioinformatics approach to identify a non-coding regulatory variant, located in an intron of the MERTK gene, based on differential transcription factor binding between the alleles. We validated the results using expression reporter assays and electrophoresis mobility shift assays. RESULTS: Chromatin immunoprecipitation sequencing indicated that transcription factor(s) bind stronger to the A allele of rs6726639. Electrophoresis mobility shift assays supported these findings and suggested that the transcription factor is interferon regulatory factor 1 (IRF1). Luciferase report assays showed lower enhancer activity from the A allele and that IRF1 may act as a repressor. CONCLUSIONS: Treatment of hepatitis C with interferon-α results in increased IRF1 levels and our data suggest that this leads to an allele-specific downregulation of MERTK mediated by an allelic effect on the regulatory element containing the functional rs6726639. This variant also shows the hallmarks for being the driver of the genome-wide association studies for reduced risk of liver fibrosis and non-alcoholic fatty liver disease at MERTK.
AIM: Infection by hepatitis C virus (HCV) can result in the development of liver fibrosis and may eventually progress into cirrhosis and hepatocellular carcinoma. However, the molecular mechanisms for this process are not fully known. Several genome-wide association studies have been carried out to pinpoint causative variants in HCV-infectedpatient cohorts, but these variants are usually not the functional ones. The aim of this study was to identify the regulatory single nucleotide polymorphism associated with the risk of HCV-induced liver fibrosis and elucidate its molecular mechanism. METHODS: We utilized a bioinformatics approach to identify a non-coding regulatory variant, located in an intron of the MERTK gene, based on differential transcription factor binding between the alleles. We validated the results using expression reporter assays and electrophoresis mobility shift assays. RESULTS: Chromatin immunoprecipitation sequencing indicated that transcription factor(s) bind stronger to the A allele of rs6726639. Electrophoresis mobility shift assays supported these findings and suggested that the transcription factor is interferon regulatory factor 1 (IRF1). Luciferase report assays showed lower enhancer activity from the A allele and that IRF1 may act as a repressor. CONCLUSIONS: Treatment of hepatitis C with interferon-α results in increased IRF1 levels and our data suggest that this leads to an allele-specific downregulation of MERTK mediated by an allelic effect on the regulatory element containing the functional rs6726639. This variant also shows the hallmarks for being the driver of the genome-wide association studies for reduced risk of liver fibrosis and non-alcoholic fatty liver disease at MERTK.
Authors: Amanda L Evans; Jack W D Blackburn; Kyle Taruc; Angela Kipp; Brennan S Dirk; Nina R Hunt; Stephen D Barr; Jimmy D Dikeakos; Bryan Heit Journal: Mol Biol Evol Date: 2017-07-01 Impact factor: 16.240
Authors: Anna Zagórska; Paqui G Través; Lidia Jiménez-García; Jenna D Strickland; Joanne Oh; Francisco J Tapia; Rafael Mayoral; Patrick Burrola; Bryan L Copple; Greg Lemke Journal: Life Sci Alliance Date: 2020-06-22
Authors: Ammar J Alsheikh; Sabrina Wollenhaupt; Emily A King; Jonas Reeb; Sujana Ghosh; Lindsay R Stolzenburg; Saleh Tamim; Jozef Lazar; J Wade Davis; Howard J Jacob Journal: BMC Med Genomics Date: 2022-04-01 Impact factor: 3.063
Authors: Bishuang Cai; Paola Dongiovanni; Kathleen E Corey; Xiaobo Wang; Igor O Shmarakov; Ze Zheng; Canan Kasikara; Viralkumar Davra; Marica Meroni; Raymond T Chung; Carla V Rothlin; Robert F Schwabe; William S Blaner; Raymond B Birge; Luca Valenti; Ira Tabas Journal: Cell Metab Date: 2019-12-12 Impact factor: 27.287
Authors: Carlo Smirne; Cristina Rigamonti; Carla De Benedittis; Pier Paolo Sainaghi; Mattia Bellan; Michela Emma Burlone; Luigi Mario Castello; Gian Carlo Avanzi Journal: Dis Markers Date: 2019-09-08 Impact factor: 3.434